Performance by category
Death-per-report rate within each category, compared to the corpus-wide average for that same category. Ratio > 1 means this manufacturer's mortality is higher than the field for that category; ratio < 1 means lower.
| Category | Devices | Reports | Deaths | Death rate | Corpus avg | vs corpus |
|---|---|---|---|---|---|---|
| Neurovascular | 65 | 13,858 | 57 | 0.41% | 2.52% | 0.16× |
| Cranial surgery | 18 | 1,420 | 38 | 2.68% | 0.38% | 7.12× |
| CSF / ICP | 2 | 91 | 0 | 0.00% | 0.89% | 0.00× |
| Neuronavigation | 1 | 37 | 0 | 0.00% | 0.24% | 0.00× |
Temporal trajectory
Annual reports for this manufacturer's neurosurgical devices, split by FDA event type. Use it to spot inflection points (recall responses, product launches, reporting-pattern shifts).
Failure-mode signature
Per category, this manufacturer's failure-mode mix vs other manufacturers in the SAME category — an apples-to-apples comparison that strips out the confound of "which categories they happen to operate in." Click a category tab to drill in.
Highest-mortality devices
Top 10 of this manufacturer's devices ranked by death-per-report rate (minimum 100 reports to avoid small-sample noise). Click any device for its full profile.
| Device | Category | Reports | Deaths | Death rate |
|---|---|---|---|---|
| Bard Therasphere | Cranial surgery | 110 | 31 | 28.18% |
| Bard Hemashield Microvel Double Velour Graft | Neurovascular | 384 | 24 | 6.25% |
| Bard Hickman | Neurovascular | 434 | 2 | 0.46% |
| Bard Powerpicc Solo Catheter | Neurovascular | 755 | 3 | 0.40% |
| Bard Groshong | Neurovascular | 591 | 2 | 0.34% |
| Bard Groshong Nxt Clearvue | Neurovascular | 2,647 | 3 | 0.11% |
| Bard Powerpicc | Neurovascular | 2,029 | 2 | 0.10% |
| Bard Powerpicc SOLO2 | Neurovascular | 1,599 | 0 | 0.00% |
| Bard Pelvisoft Acellular Collagen Biomesh | Cranial surgery | 916 | 0 | 0.00% |
| Bard Picc | Neurovascular | 834 | 0 | 0.00% |